IL-HYATT-HOTELS
14.7.2022 14:02:11 CEST | Business Wire | Press release
To share progress made across World of Care, the company’s Environmental, Social and Governance (ESG) platform, Hyatt Hotels Corporation (NYSE: H) today published its 2021 World of Care Highlights and Diversity, Equity and Inclusion (DE&I) Report to demonstrate how Hyatt is advancing care for the planet, people and responsible business.
“Caring for people so they can be their best has been at the core of Hyatt’s story for 65 years. Through World of Care, we embrace our responsibility and opportunity to work together to shape a more sustainable world and future,” said Margaret Egan, executive vice president and general counsel, Hyatt. “By intently focusing on driving progress against key ESG commitments like our environmental framework and Change Starts Here goals, we are holding ourselves accountable for continued action and progress in order to create the needed changes for our industry, society and planet.”
Hyatt Advances Diverse Workforce Representation
Following last year’s inaugural DE&I report, Hyatt’s 2021 workforce diversity data shows increased levels of representation of people of color across its U.S. workforce, as well as growth across nearly all races and ethnicities among colleagues, managers and leaders. Hyatt’s commitment to share progress annually serves as a critical benchmark to measure the strides made toward a more diverse, equitable and inclusive environment for colleagues.
Hyatt continues to work toward its 2025 DE&I goals around who it employs, supports and works with, outlined as part of its Change Starts Here commitments. With a focus on improving diverse vendor representation across its supply chain, Hyatt welcomed 220 new Black suppliers in 2021, with a continued focus on advancing progress looking ahead. For example, Revival Baltimore, which is part of the JdV by Hyatt brand, worked with Black-owned Black Acres Roastery to supply coffee to all hotel guestrooms and the property’s onsite coffee shop, ‘Dashery, and Hyatt Centric The Pike Long Beach recently welcomed Black-owned brewery Crowns & Hops to its Watercraft Lounge.
“At Hyatt, we believe in the power of belonging – of making people feel at home no matter where they are in the world. We constantly strive to reflect the world we care for with teams that achieve and grow together,” said Malaika Myers, chief human resources officer, Hyatt. “To advance our vision of a world of understanding and care, we must continue to prioritize DE&I across every dimension of our business and take action to make meaningful progress against our goals.”
Hyatt Announces Donation to Launch Human Trafficking Survivor Fund
In an effort to expand the hotel industry’s ongoing work to support human trafficking prevention and survivors, the Hyatt Hotels Foundation has announced a $500,000 donation to launch the “No Room for Trafficking Survivors Fund” in collaboration with the American Hotel & Lodging Association (AHLA). With the donation, and further support from the industry, the Survivors Fund will equip community-based organizations with the resources they need to engage and support survivors – from direct financial support of their short-term, baseline needs to career-related support that can empower and equip them on their path forward.
Hyatt Works to Advance Climate Action
Hyatt further accelerates its efforts to engage in more sustainable business practices as part of its environmental framework – focused on areas of climate change and water conservation, waste and circularity, responsible sourcing and thriving destinations.
In 2021, Hyatt received approval from the Science Based Targets initiative (SBTi) on its 2030 science-based target to reduce greenhouse gas emissions. Hyatt’s targets include reducing absolute scope 1 and 2 emissions, engaging key suppliers to set science-based targets by 2025, and decreasing additional scope 3 emissions.
Hyatt remains diligent in promoting initiatives that support progress toward its science-based target, which focus on energy conservation, efficient technology, building automation systems, advancing sustainable design considerations and more. An important ongoing focus will be on increasing the number of hotels that have on-site solar panels or are using one-hundred percent renewable electricity such as Hyatt Regency Amsterdam and Hyatt Regency Phoenix. Ongoing property efforts are also critical in achieving these targets, such as the ones displayed at Alila Villas Uluwatu through its on-site sustainability lab .
To learn more about Hyatt’s ESG efforts and progress, visit Hyatt.com/WorldofCare or browse the 2021 World of Care Highlights , 2021 DE&I Report and 2021 GRI Index .
The term “Hyatt” is used in this release for convenience to refer to Hyatt Hotels Corporation and/or one or more of its affiliates.
About Hyatt Hotels Corporation
Hyatt Hotels Corporation, headquartered in Chicago, is a leading global hospitality company guided by its purpose – to care for people so they can be their best. As of March 31, 2022, the Company’s portfolio included more than 1,150 hotels and all-inclusive properties in 71 countries across six continents. The Company's offering includes the Park Hyatt®, Miraval®, Grand Hyatt®, Alila®, Andaz®, The Unbound Collection by Hyatt®, Destination by Hyatt™, Hyatt Regency®, Hyatt®, Hyatt Ziva™, Hyatt Zilara™, Thompson Hotels®, Hyatt Centric®, Caption by Hyatt, JdV by Hyatt™, Hyatt House®, Hyatt Place®, UrCove, and Hyatt Residence Club® brands, as well as resort and hotel brands under the AMR™ Collection, including Secrets® Resorts & Spas, Dreams® Resorts & Spas, Breathless Resorts & Spas®, Zoëtry® Wellness & Spa Resorts, Vivid Hotels & Resorts®, Alua Hotels & Resorts®, and Sunscape® Resorts & Spas. Subsidiaries of the Company operate the World of Hyatt® loyalty program, ALG Vacations®, Unlimited Vacation Club®, Amstar DMC destination management services, and Trisept Solutions® technology services. For more information, please visit www.hyatt.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005967/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
